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Abstract
Background: Treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is a well-established
therapy for advanced Hodgkin’s lymphoma (HL). However, the recently completed ECHELON-1 trial showed
potential net clinical benefit for brentuximab vedotin (BREN+AVD) compared to ABVD as frontline therapy in
patients with advanced Hodgkin’s lymphoma. The objective of this analysis is to determine whether, on current
evidence, BREN+AVD is cost-effective relative to ABVD as frontline therapy in patients with advanced HL.
Methods: We constructed a probabilistic Markov model with two arms and six mutually exclusive health states,
using six-month cycle lengths, and a 15-year time horizon. Time-dependent transition probabilities were calculated
from ‘real-world’ data collected by the BC Cancer’s Centre for Lymphoid Cancer database or from the literature for
ABVD. Time-dependent transition probabilities for BREN+AVD were taken from the ECHELON-1 trial. We estimated
the incremental cost and effects per patient of each therapy and calculated the incremental cost-effectiveness ratio
(ICER). Costs were measured in 2018 Canadian dollars and effects measured in quality-adjusted life years (QALYs). A
probabilistic analysis was used to generate a cost-effectiveness acceptability curve (CEAC).
Results: The incremental cost between standard therapy with ABVD and therapy with BREN+AVD was estimated to
be $192,336. The regimen of BREN+AVD resulted in a small benefit in terms of QALYs (0.46 QALYs). The estimated
ICER was $418,122 per QALY gained. The probabilistic analysis suggests very few (8%) simulations fall below
$100,000 per QALY. Even at a threshold of $200,000 per QALY gained, there was only a 24% chance that
BREN+AVD would be considered cost-effective. Sensitivity analyses evaluating price reductions for brentuximab
showed that these reductions needed to be in excess of 70% for this regimen to be cost-effective at a threshold of
$100,000 per QALY.
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Conclusions: There may be a clinical benefit associated with BREN+AVD, but on current evidence the benefit is not
adequately substantive compared to ABVD therapy given the cost of brentuximab vedotin. Agencies responsible for making
decisions about BREN+AVD as frontline therapy for patients with advanced HL should consider whether they are willing to
implement this treatment given the current uncertainty and cost-benefit profile, or negotiate substantial price-reductions
from the manufacturer should they choose to reimburse.
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Background
Hodgkin’s lymphoma (HL) is a disease of the lymphatic
system, affecting approximately 1000 people per year in
Canada [1, 2]. In adults, diagnosis most commonly oc-
curs between ages 20 and 39, or later in life for those
over aged 55 years [3].
The prognosis for patients with advanced HL is favor-
able relative to other advanced cancers. Current evi-
dence suggests that greater than 80% of HL patients will
enter a state of complete remission on standard therapy
[4, 5]. For patients with advanced HL, the standard ther-
apy is comprised of doxorubicin, bleomycin, vinblastine,
and dacarbazine (ABVD). The bleomycin component of
ABVD therapy is unpredictable and is often associated
with toxicity, and results in adverse events. While the
bleomycin component of ABVD therapy has been shown
to be associated with toxicity, it should be noted that re-
cent studies have suggested that use of a positron emis-
sion tomography (PET) scan to guide treatment might
reduce the risk of adverse events, and enable physicians
to remove bleomycin from the final cycles of treatment
[6]. Also requiring consideration is the fact that while
ABVD therapy is well-established, there remains a per-
centage (30–40%) of patients that will require more ag-
gressive therapies, due to disease relapse or primary
refractory disease [7, 8]. Approximately 20% of patients
who are not cured with first-line treatment will die after
relapse or progression [9].
The ECHELON-1 trial tested brentuximab vedotin plus
doxorubicin, vinblastine, and dacarbazine (BREN+AVD)
versus ABVD therapy [10]. Brentuximab vedotin is an
antibody-drug conjugate that targets the protein CD30 in
HL patients [11]. Brentuximab vedotin, in combination
with AVD therapy, was examined in the ECHELON-1 trial
as a potentially promising treatment that could replace
ABVD as standard frontline care for advanced-stage HL
patients [10]. The results of the trial showed improved dif-
ferences for patients treated with BREN+AVD in terms of
modified progression free survival (HR: 0.77 (95% CI:
0.60–0.98)) but no statistically significant improvement in
overall survival (HR: 0.72 (95% CI: 0.44–1.17)) [10].
While the results of the ECHELON-1 trial suggest a
potential net clinical benefit in terms of modified pro-
gression free survival from treatment with BREN+AVD,
the price of BREN+AVD is substantially higher than
ABVD therapy. While there may be evidence of a net
clinical benefit associated with BREN+AVD as frontline
therapy in patients diagnosed with advanced HL, there
remains uncertainty as to whether or not this therapy is
cost-effective, particularly from a Canadian perspective,
when compared to more established therapies. This ana-
lysis reports on the results of a cost-effectiveness analysis
of ABVD compared to BREN+AVD used as frontline
therapy for patients with advanced stage Hodgkin's
lymphoma from the perspective of the Canadian prov-
ince of British Columbia.
Methods
Modeling overview
A state-transition Markov model was constructed with
two treatment arms. In one arm, patients would receive
therapy with BREN+AVD; in the other, patients would
receive the current standard of care, ABVD. Both arms
were structurally identical and consisted of six potential
health states: (i) treatment with the relevant therapy; (ii)
complete remission after initial treatment; (iii) progres-
sion or relapse after initial treatment (and potential re-
ceipt of autologous stem cell transplant (ASCT)); (iv)
remission after second treatment with ASCT; (v) second
progression or relapse (resulting in ‘salvage’ therapy with
pembrolizumab); and, (vi) death (see Fig. 1). Each of the
health states are mutually exclusive – meaning that a pa-
tient can only be in one specific health state during each
model cycle. Each model cycle was assumed to be 6
months long, and the model time horizon was 15 years.
While the structure of the model was identical for both
arms, the data used to populate the models (i.e., prob-
abilities, costs) were specific to each of the respective
therapies. Additional details of the model structure are
available in the Supplementary Material.
Within each specific health state, further events were
possible. For example, in the initial treatment cycle, pa-
tients were able to experience complete remission, an
adverse event, treatment discontinuation, or death. The
probabilities of each of these potential events were based
on data for that particular therapy and are presented,
with sources, in Table 1. The model was used to esti-
mate the costs and effects of the experimental arm
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(BREN+AVD) and the standard of care arm (ABVD).
The incremental costs and incremental effects from each
arm were then used to estimate the incremental cost-
effectiveness ratio (ICER). The modeling approach taken
was consistent with guidelines produced in Canada for
the economic evaluation of health technologies by the
Canadian Agency for Drugs and Technologies in Health
(CADTH) [18]. The model was programmed in TreeAge
Pro 2018 (TreeAge Software; Williamstown, USA). Eth-
ics approval for this study was obtained by the Univer-
sity of British Columbia – BC Cancer Research Ethics
Board (H18–00490).
Transition probabilities
Real-world data to inform the standard of care (ABVD)
arm of the model were obtained from the BC Cancer’s
Centre for Lymphoid Cancer (CLC) database. The CLC
database houses data on treatment, response to treat-
ment, and dates of significant clinical events for patients
with lymphoid cancer in the province of BC. Included
patients were greater or equal to 18 years of age and
were diagnosed between 2000 and 2016 in BC. To avoid
potential interactions with other conditions, patients
who were HIV-positive and/or pregnant at time of diag-
nosis were also excluded from our sample. After these
criteria were applied, a cohort of 1519 patients was
established which was used to calculate transition prob-
abilities for the standard care arm of the model. To de-
rive transition probabilities for standard care (ABVD),
we calculated the time elapsed between events of inter-
est reported in the CLC database (i.e., the transitions be-
tween health states in the Markov model), and then fit a
Weibull distribution to the data. From the fitted Weibull
distribution, we then computed probabilistic beta-
distributed transition probabilities. For BREN+AVD,
time-dependent probabilities were extracted from pub-
lished data. Details of specific sources for the data are
available in Table 1.
To derive transition probabilities for the BREN+AVD
arm, the statistical analysis software ‘R’ (Version 3.6.1;
Vienna, Austria) and package FlexSurv [19] were used to
perform Weibull regression on digitized published data
from the ECHELON-1 trial [10]. Variance was calculated
using the Hessian at the maximum, transformed back to
the original scale of the parameters at each time point [19].
Future transition probabilities were calculated using the cal-
culated Weibull curve and the standard error of prediction
at each time point [20, 21]. Additional probabilities were
obtained from relevant literature [12, 13] (see Table 1).
Costs and utilities
The costs for both BREN+AVD and ABVD therapy are
based on the Canadian list prices for these regimens. All
other costs were taken from the literature [14–16]. The
ECHELON-1 trial did not report on costs collected
alongside the trial. Costs are presented in 2018 Canadian
dollars from the health care payer perspective.
Utility estimates were taken exclusively from the litera-
ture, based largely on a study by Swinburn et al. [17].
This study focused on patients specifically with relapsed/
refractory disease but provided utility estimates, using
the time trade-off (TTO) method, for patients with a
complete response, stable disease, experiencing adverse
events, and with progressive disease. The study pre-
sented data for several countries; in the reference case
analysis we have used estimates from the United King-
dom (n = 100). All costs and outcomes were discounted
at 1.5% per year.
Fig. 1 Conceptual diagram of possible model transitions
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Model assumptions
Utility values for all health states for ABVD and BREN+
AVD are the same. This assumption is largely a result of
a dearth of original health-related quality of life
(HRQoL) data being collected or reported for HL pa-
tients, including HRQoL data being reported from
ECHELON-1 [22]. We have assumed a price of BREN+
AVD therapy of $116,160 CAD which is based on the
list price for six cycles of BREN+AVD therapy. The as-
sumed cost and number of cycles for BREN+AVD is
based on the ECHELON-1 trial but this may be variable
in practice based on the patient’s age, response to treat-
ment, and toxicity [10, 23]. Recent studies have also sug-
gested the addition of concurrent medications (i.e.,
pegfilgrastim) to reduce the risk of adverse events, which
may double the cost of the therapy [24]. Finally, evidence
Table 1 Model parameters, sources, and distributions used in the probabilistic analysis
Parameter Value Distribution Source
Probabilities
Serious adverse event (BREN+AVD) 0.429 Beta Connors et al. (2018) [10]
Serious adverse event (ABVD) 0.270 Beta Connors et al. (2018) [10]
Treatment discontinuation (BREN+AVD) 0.133 Beta Connors et al. (2018) [10]
Treatment discontinuation (ABVD) 0.159 Beta Connors et al. (2018) [10]
Mortality on treatment (BREN+AVD) 0.013 Beta Connors et al. (2018) [10]
Mortality on treatment (ABVD) 0.019 Beta Connors et al. (2018) [10]
Progression/relapse while in complete remission (BREN+AVD) Time Dep Beta Connors et al. (2018) [10]
Mortality in complete remission (BREN+AVD) Time Dep Beta Connors et al. (2018) [10]
Progression/relapse while in complete remission (ABVD) Time Dep Beta CLC
Mortality in complete remission (ABVD) Time Dep Beta CLC
Eligible for ASCT (BREN+AVD or ABVD) 0.8 Beta Expert Opinion
Mortality in progression/relapse (ABVD) Time Dep Beta Vivani et al. (2011) [12]
Mortality in progression/relapse (BREN+AVD) Time Dep Beta Vivani et al. (2011) [12]
Successful ASCT 0.5 Beta Expert Opinion
Progression/relapse post-ASCT (BREN+AVD) Time Dep Beta CLC
Progression/relapse post-ASCT (ABVD) Time Dep Beta CLC
Mortality post-ASCT progression/relapse (BREN+AVD or ABVD) Time Dep Beta Chen et al. (2016) [13]
Costs
Cost BREN+AVD $116,160 Gamma Canadian list price for six cycles
Cost ABVD $12,701 Gamma Canadian list price for six cycles
PET scan $1877 Gamma Cerci et al. (2010) [14]
Cost of adverse event (ABVD or BREN+AVD) $12,036 Gamma Wong et al. (2018) [15]
ASCT $67,723 Gamma Bloomstein et al. (2012) [16]
Salvage chemotherapy for non-responders $140,800 Gamma Canadian list price for six cycles
Utility values
Receiving treatment (ABVD or BREN+AVD) 0.71 Beta Swinburn et al. (2015) [17]
Complete remission 0.91 Beta Swinburn et al. (2015) [17]
Adverse event 0.59 Beta Swinburn et al. (2015) [17]
Progressive disease 0.38 Beta Swinburn et al. (2015) [17]
Model details
Cycle length 6 months Assumed
Time horizon 15 years Assumed
Cost year 2018 Assumed
Discount rate: costs 1.5% Assumed
Discount rate: effects 1.5% Assumed
Time Dep time-dependent transition probability. CLC Centre for Lymphoid Cancer
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also suggests that bleomycin may be removed from the
final cycles of ABVD therapy which reduces the prob-
ability of adverse events, but we have kept bleomycin in-
cluded in ABVD therapy as a conservative assumption.
Probabilistic analyses
A probabilistic analysis was conducted using Monte
Carlo simulation with 10,000 iterations from appro-
priate distributions of the input parameters (see Table
1). The probabilistic analysis generated a range of
ICERs, which were plotted on the cost-effectiveness
plane. The cost-effectiveness plane plots the incre-
mental costs (y-axis) and incremental benefit in terms
of QALYs (x-axis) for each model simulation. The
probabilistic analysis was also used to generate a
cost-effectiveness acceptability curve (CEAC). The
CEAC shows the probability of whether or not a par-
ticular treatment regimen will be cost-effective at dif-
ferent levels of willingness-to-pay for an additional
QALY. Finally, given the considerable variability in re-
ported costs of brentuximab vedotin and the potential
for price negotiations if chosen for reimbursement,
we conducted specific scenario analyses using differ-
ent prices of this treatment regimen.
Results
The results of this economic evaluation suggest a sub-
stantial estimated incremental cost between the standard
therapy with ABVD and therapy with BREN+AVD
($192,336) and a small benefit in terms of QALYs (0.46
QALYs). This resulted in an estimated ICER of $418,122
per QALY gained (Table 2). While Canada has no
explicit willingness-to-pay threshold per QALY gained,
this exceeds commonly cited thresholds of $50,000 or
$100,000 per QALY gained, indicating that BREN+AVD
therapy is unlikely to be cost-effective compared to
ABVD therapy.
The cost-effectiveness plane of each ICER calculation
is presented in Fig. 2 and the CEAC is in Fig. 3. The
probabilistic analysis showed that only 8% of model sim-
ulations resulted in an ICER less than a $100,000 per
QALY threshold, and less than 1% simulations were as-
sociated with greater effects and lower costs for BREN+
AVD versus the standard of care. Importantly, the un-
certainty associated with BREN+AVD therapy was dem-
onstrated in that approximately 20% of simulations
suggested that this therapy resulted in lower incremental
effects and greater incremental costs than ABVD ther-
apy. In Fig. 3, the CEAC shows that when a threshold of
$100,000 per QALY gained is used, there is an approxi-
mately 10% chance of treatment with BREN+AVD being
cost-effective.
Given a potential clinical benefit from BREN+AVD
therapy but that our analysis suggested that BREN+
AVD was not cost-effective, the price of this therapy
was adjusted to evaluate at what cost the therapy
could be considered cost-effective relative to ABVD.
In this analysis, a greater than 70% reduction in the
cost of BREN+AVD was required for this therapy to
be a cost-effective alternative to ABVD at a threshold
of $100,000 per QALY.
Discussion
This analysis evaluated the cost-effectiveness of a treat-
ment regimen including brentuximab vedotin, compared
to standard therapy with ABVD, as frontline therapy for
patients with advanced HL in British Columbia, Canada.
The recent phase III trial ECHELON-1 reported that
treatment for patients with advanced HL with brentuxi-
mab vedotin was shown to offer a net clinical benefit
using a surrogate outcome measure (modified
progression-free survival) compared to the standard of
care (ABVD). However, our economic evaluation has
shown that the benefit associated with BREN+AVD
therapy is unlikely to be commensurate with the high
cost of this therapy. This result is reinforced given that
there is reliable long-term real-world evidence for the ef-
fectiveness of ABVD therapy, while the evidence for
BREN+AVD therapy relies on limited and short-term ef-
ficacy data from a phase III trial [10].
Previous economic evaluations of brentuximab vedotin
as frontline treatment for advanced HL have come to
conflicting conclusions. Delea et al. [25], also using data
from the ECHELON-1 trial reported an ICER of
$172,074 per QALY (using the overall study population
from ECHELON-1) or $69,442 per QALY gained when
the study population was restricted to data from North
American sites. This analysis assumed favorable benefits
for brentuximab vedotin as it relied on key assumptions
including investigator-reported data (as opposed to that
assessed by an independent review committee) and used
modified progression free survival as the effectiveness
Table 2 Results from the reference case probabilistic analysis (95% confidence intervals)
Treatment Cost (CAD$) Effect (QALYs) Incremental Cost Incremental Effect ICER
BREN + AVD $411,190 9.62 $192,336 0.46 $418,122
($300,490–$554,715) (7.29–11.0)
ABVD $218,854 9.16
($156,367–$310,743) (6.98–10.49)
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Fig. 2 Scatter plot of incremental cost-effectiveness ratios (ICERs) generated from the probabilistic analysis (n = 10,000 iterations)
Fig. 3 Cost-effectiveness acceptability curve showing the probability that therapy including brentuximab vedotin is cost-effective at various levels
of willingness-to-pay (WTP) per QALY gained
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measure for a select population in North America. Based
on these results, the authors concluded that it was likely
to be cost-effective in this patient population [25]. In
contrast, Huntington et al. [26] conducted a cost-utility
analysis based on the results of the ECHELON-1 trial
and drew comparable conclusions to our own, finding
an ICER of $317,254 per QALY gained, largely due to
the small incremental gain in QALYs between BREN+
AVD and ABVD (0.56 QALYs). The authors also noted
that there was a lack of HRQoL (utility) data for BREN+
AVD and ABVD therapy to inform the QALY
calculation.
Given the reported net clinical benefit from BREN+
AVD therapy [10], an analysis was conducted to de-
termine at what cost BREN+AVD would be cost-
effective for the treatment of advanced HL patients.
Similar to the analysis conducted by Huntington et al.
[26] we carried out a series of sensitivity analyses to
determine at what price BREN+AVD is required to
be in order to be considered cost-effective at an as-
sumed threshold of $100,000 per QALY gained. It
should be noted that other studies have reported
higher cost of therapy with BREN+AVD [24]. The im-
plication of a higher cost for BREN+AVD is obvious;
the result would be an even lower probability that it
would be cost-effective as frontline therapy given the
current state of evidence. The value of any new ther-
apy is relative to what is currently used in practice,
so the increment that the health care provider should
be willing to pay, based on the value, could poten-
tially set the price. Our probabilistic analysis pro-
duced an important result. The uncertainty associated
with the treatment effect of BREN+AVD resulted in a
considerable number of simulations with a negative
incremental benefit, favouring treatment with ABVD.
Brentuximab vedotin and the ECHELON-1 trial
provide a perfect example of some of the deficiencies
of current clinical trials in informing reimbursement
decision-making. Frontline therapy for patients with
advanced HL, as stated, is well-established. As such,
we were able to obtain real-world data from patients
treated at BC Cancer to populate our economic
model. This can be contrasted with the estimated
beneficial effect in ECHELON-1, a small, albeit statis-
tically significant increase in a surrogate outcome
measure, modified progression-free survival. The im-
plication is that the use of surrogate outcome mea-
sures should be interpreted cautiously, and should not
be sufficient to alter clinical practice in place of more
established outcomes (i.e., overall survival), which is a
better metric of a treatment value [24]. Moreover, if
this use of surrogate outcome measures is coupled
with a failure to collect (or report) HRQoL data the
trial has almost certainly failed to collect data that
matters to patients, and by extension, decision-
makers.
Limitations
There are limitations to our study that require acknow-
ledgement. First, several model parameters are based on
necessary assumptions for our model. Utility values, for
example, used to calculate QALYs were not original data
collected alongside the ECHELON-1 trial and were
taken from a previous study [17]. To the best of our
knowledge, the ECHELON-1 trial did not report on
HRQoL data (if collected) that could be used for eco-
nomic analysis, which is common for oncology clinical
trials [27]. Similarly, our analysis assumed that treatment
costs were based on Canadian list prices and did not in-
clude additional associated costs. Second, economic
models representing disease pathways are always a sim-
plification of reality, and there are different trajectories
that individual patients might take that are not repre-
sented by our model structure. In order to be able to
provide economic evidence to decision-makers, however,
these simplifications are necessary. We have attempted
to mitigate these simplifications by engaging clinical ex-
perts in HL to provide face validity to our model. Third,
for the time horizon to be suitably long enough given
this disease area, we extrapolated reported survival
curves to 15 years, but acknowledge that, if the data were
available, a lifetime time horizon would be superior. Fi-
nally, although we have reported that BREN+AVD is un-
likely to be a cost-effective use of health resources, as
with any economic evaluation, there are factors beyond
what might be included in the analysis, which should be
considered in relation to whether or not a drug is ultim-
ately reimbursed.
Conclusions
For patients with advanced Hodgkin’s Lymphoma, the
minimal treatment gains that can be achieved through a
therapy containing brentuximab vedotin do not appear
to warrant the cost based on current evidence. While
ECHELON-1 showed a net clinical benefit in terms of a
surrogate endpoint resulting from a therapy with bren-
tuximab vedotin, we have shown that at its current price,
it would be an inefficient use of health care resources.
Importantly, the manufacturers might heed the results
of this study to decrease the price of therapy commen-
surate to its benefits and continue to collect evidence for
its effectiveness. Coupled with high cost of brentuximab
is the uncertainty in its use compared to the real-world
data of a long established and beneficial therapy
(ABVD). This analysis highlights the value of real-world
data in helping inform decisions about the funding of
new therapies with short-term or limited evidence com-
pared to established therapies.
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